TY - JOUR
T1 - Tumorigenesis in neurofibromatosis
T2 - New insights and potential therapies
AU - Reed, Nevada
AU - Gutmann, David H.
PY - 2001
Y1 - 2001
N2 - The neurofibromatoses NF1 and NF2 are inherited cancer predisposition syndromes in which affected individuals are prone to development of mostly benign, but occasionally malignant, tumors. The NF1 and NF2 genes function as tumor suppressor genes (negative growth regulators), such that their loss of expression predisposes to tumor formation. Neurofibromin, the protein product of the NF1 gene, acts as a negative regulator of the ras proto-oncogene, to reduce cell growth. Merlin, the NF2 gene product, is involved in regulating cell proliferation and motility, and probably plays a role in integrating multiple cell-signaling pathways. By understanding the function of these tumor suppressors, we have a unique opportunity to develop targeted pharmacotherapeutic interventions for these disorders.
AB - The neurofibromatoses NF1 and NF2 are inherited cancer predisposition syndromes in which affected individuals are prone to development of mostly benign, but occasionally malignant, tumors. The NF1 and NF2 genes function as tumor suppressor genes (negative growth regulators), such that their loss of expression predisposes to tumor formation. Neurofibromin, the protein product of the NF1 gene, acts as a negative regulator of the ras proto-oncogene, to reduce cell growth. Merlin, the NF2 gene product, is involved in regulating cell proliferation and motility, and probably plays a role in integrating multiple cell-signaling pathways. By understanding the function of these tumor suppressors, we have a unique opportunity to develop targeted pharmacotherapeutic interventions for these disorders.
UR - http://www.scopus.com/inward/record.url?scp=0035057686&partnerID=8YFLogxK
U2 - 10.1016/S1471-4914(01)01955-4
DO - 10.1016/S1471-4914(01)01955-4
M3 - Review article
C2 - 11286939
AN - SCOPUS:0035057686
SN - 1471-4914
VL - 7
SP - 157
EP - 162
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
IS - 4
ER -